南方医科大学学报

南方医科大学学报 ›› 2004, Vol. 24 ›› Issue (09): 1061-1063.

• • 上一篇    下一篇

ZD1839治疗晚期非小细胞肺癌的临床观察

张琳   

  1. 解放军第309医院呼吸科, 北京, 100091
  • 出版日期:2004-09-20 发布日期:2004-09-20
  • 基金资助:
    收稿日期:2004-1-21。
    作者简介:张琳(1967-),男,2002年毕业于第一军医大学,硕士,主治医师,电话:010-66775065

Clinical observation of ZD1839 in treating 32 cases of non-small-cell lung cancer

ZHANG Lin   

  1. 解放军第309医院呼吸科, 北京, 100091
  • Online:2004-09-20 Published:2004-09-20

PDF

1623

摘要： 目的 观察ZD1839治疗晚期非小细胞肺癌的疗效和毒副作用。方法 以一定的标准选取32例晚期非小细胞肺癌病人,口服ZD1839治疗,90 d后观察其疗效及毒副反应。结果 完全缓解(CR)0%,部分缓解(PR)18.75%,稳定(SD)37.50%,疾病控制率(CR+PR+SD)56.25%。毒副作用中,出现痤疮样皮疹10例(31.25%),腹泻6例(18.75%),转氨酶升高4例(12.50%),恶心、呕吐5例(15.63%),未发现间质性肺炎病例。结论 ZD1839是一种新药,其疾病控制率和毒副作用对于肺癌患者来说是可以接受的,在治疗肺癌方面具有良好的前景。

Abstract: Objective To study e the therapeutic and adverse effects of ZD1839 in treating non-small-cell lung cancer (NSCLC). Methods The therapeutic and adverse effects of ZD1839 given orally were observed in 32 NSCLC cases after a treatment course more than 90 d. Results The rates of complete remission (CR), partial remission (PR), and stabilization (SD) were 0%, 18.75%, and 37.50% respectively, with a disease control rate of 56.25%. The adverse effects of this agent included acneiform rash, diarrhea, aminotransferase elevation, nausea and vomiting, occurring in 31.25%, 18.75%, 12.50% and 15.63% of the cases respectively. No interstitial lung disease was found. Conclusion ZD1839 is a new drug produeing acceptable disease control rate along with tolerable adverse effects in patients with lung cancer.

中图分类号: